Key highlights

  • Vectus Biosystems shares were down 7.90% at $0.070 during the 10 November 2026 trading session.
  • The US Food and Drug Administration granted the company's request for a pre-IND Type B meeting on VB0004.
  • Written FDA responses are expected by mid-November 2026.

Vectus Biosystems Ltd (ASX:VBS) fell 7.90% to $0.070 during the 10 November 2026 trading session. The S&P/ASX 200 was higher by 1.34%, or 121.20 points, at 9,150.90 over the same session. Vectus is developing VB0004, a first-in-class oral compound for idiopathic pulmonary fibrosis. Its latest update was its Appendix 4C and quarterly activities report for the quarter ended 30 September 2026, released on 29 October 2026.

FDA pre-IND meeting

During the quarter the company progressed its US regulatory pathway after the FDA granted its request for a pre-IND Type B meeting on the proposed development program for VB0004 in idiopathic pulmonary fibrosis.

The interaction will take the form of written FDA responses, which are expected in mid-November 2026. Vectus and its US regulatory agent began finalising the meeting package for submission.

Regulatory agent and clinical background

Cardinal Health Regulatory Services has been appointed as Vectus's US regulatory agent to prepare and facilitate FDA communications and submissions.

VB0004 has completed a Phase Ia study in healthy volunteers, which the company says established a favourable early profile for further development.

Sector context

Developers of drugs for idiopathic pulmonary fibrosis operate in a field with significant unmet need and a high level of regulatory scrutiny. Investors in early-stage companies often wait for formal FDA feedback before reassessing development plans. At about 7 cents, Vectus trades in Penny Stock territory, and the broader market was higher during the session.

Risks

The FDA's written responses will provide guidance, but they do not guarantee that the proposed program will be accepted as planned. The company may need to change its design or add studies.

Early-stage data from healthy volunteers do not show efficacy in patients with the disease, and any clinical program will carry trial risk.

What to watch ahead

Investors will be looking for the FDA's written responses in mid-November, the next steps in the clinical and regulatory program and the December quarter report.

Final Word

Vectus's Trading session fall came as the company awaited FDA feedback on its pre-IND meeting request. The formal written responses will guide the next stages of VB0004's development.